|
|
LETTER TO THE EDITOR |
|
Year : 2019 | Volume
: 67
| Issue : 2 | Page : 312 |
|
Response to comment on: Validating the pachychoroid disease spectrum using multimodal imaging
Guruprasad Ayachit, Apoorva Ayachit, Harsha Nadgir, Shrinivas Joshi
Department of Vitreoretina, M. M. Joshi Eye Hospital, Hosur, Hubli, Karnataka, India
Date of Web Publication | 23-Jan-2019 |
Correspondence Address: Dr. Apoorva Ayachit M. M. Joshi Eye Hospital, Gokul Road, Hosur, Hubli - 580 021, Karnataka India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijo.IJO_1870_18
How to cite this article: Ayachit G, Ayachit A, Nadgir H, Joshi S. Response to comment on: Validating the pachychoroid disease spectrum using multimodal imaging. Indian J Ophthalmol 2019;67:312 |
How to cite this URL: Ayachit G, Ayachit A, Nadgir H, Joshi S. Response to comment on: Validating the pachychoroid disease spectrum using multimodal imaging. Indian J Ophthalmol [serial online] 2019 [cited 2019 Dec 8];67:312. Available from: http://www.ijo.in/text.asp?2019/67/2/312/250669 |
Dear Sir,
We thank Sheth et al. for their interest in our case. They present a very well-illustrated follow-up of a case of pachychoroid over 4 years.[1]
In their case, there is a progression of pachychoroid pigment epitheliopathy (PPE) to central serous chorioretinopathy (CSC), pachychoroid neovasculopathy (PCN), and finally polypoidal choroidal vasculopathy (PCV). This progression is well known in the pathogenesis of pachychoroid disease spectrum. The novelty of our case, however, was simultaneous presentation of both CSC and PCV along with emphasis on optical coherence tomography angiography features. Polyps and choroidal neovascularization in the setting of chronic CSC are well known.[2] This aspect is getting increased attention since the introduction of the concept of pachychoroid. We wish to reiterate that the key focus of our case was the possibility of simultaneously having both CSC and PCV as also illustrated in a series by Manayath et al.[3]
We feel that Dr. Sheth's case would have been an interesting adjunct to our case had they shown an example where there were PPE, CSC, neovasculopathy, and PCV at the same point in time. We agree that our patient did not have PCN in addition to having PPE, CSC, and PCV. Their case merely shows progression of pachychoroid and not simultaneous presentation like in our case. It seems like an addition only because of the demonstration of imaging features of PCN, in a longitudinal follow-up.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
References | |  |
1. | Sheth JU, Giridhar A. Comment on: Validating the pachychoroid disease spectrum using multimodal imaging. Indian J Ophthalmol 2019;67:310-1. [Full text] |
2. | Park H, Kim I. Clinical characteristics of polypoidal choroidal vasculopathy associated with chronic central serous chorioretionopathy. Korean J Ophthalmol 2012;26:15. |
3. | Manayath G, Shah V, Saravanan V, Narendran V. Polypoidal choroidal vasculopathy associated with central serous chorioretinopathy: Pachychoroid spectrum of diseases. Retina 2018;38:1195-204. |
|